INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology
Oral Presentation to Highlight Preclinical Data on a Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cell Therapy (CD19.taNK) in CD Resistant B-Cell Non-Hodgkin Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
View HTML
Toggle Summary NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer (haNK) Cells
Successful Administration Of Off The Shelf Hank Cells In Patients With Solid Tumors Paves The Way To Nation's First Combination Innate And Adaptive NANT Cancer Vaccine Trials In Multiple Tumor Types CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 2, 2017-- NantKwest Inc.
View HTML
Toggle Summary NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors
CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 22, 2017-- NantKwest, Inc. (Nasdaq:NK) today announced that Fred Driscoll , currently an Advisor and former Chief Financial Officer of Flexion Therapeutics, Inc. , has been appointed to the Board to fill the position being vacated by Mr.
View HTML
Toggle Summary NantKwest to Present at Upcoming Investment Conferences
CULVER CITY, CALIFORNIA-(BUSINESS WIRE), September 5, 2017 NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at three investment conference in September.
View HTML
Toggle Summary NantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Aug. 7, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting at the 37 th Annual Canaccord Genuity Growth Conference taking place August 9-10, 2017 in
View HTML
Toggle Summary NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies
42% Of Patents Exhibited A Response, With Two Complete Responses In A Phase 1 Study Of 12 Patients With A Patient In Complete Remission 10 Years After Failing Transplant Therapy For Hodgkin’s Lymphoma, And A Second Patient In Complete Remission 2 Years After Failing Transplant Therapy In Multiply
View HTML
Toggle Summary NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials
CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 25, 2017-- NantKwest Inc. (Nasdaq:NK), a clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases, today announced a
View HTML
Toggle Summary NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease
First Combination Off The Shelf NK And Adaptive Immunotherapy Trial To Be Initiated For Pancreatic, Lung, Breast, Colon, Melanoma, Sarcoma, Chordoma, Head And Neck, Non Hodgkin’s Lymphoma, Merkel Cell And Ovarian Cancers. First Whole Genome, Transcriptomic, Proteomic (GPS Cancer) Informed
View HTML
Toggle Summary NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 2, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 th , in New York City at
View HTML
Toggle Summary NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs
Company Adds Immuno-Oncology and Clinical Trial Expert to Leadership Team CULVER CITY, Calif. --(BUSINESS WIRE)--May 18, 2017-- NantKwest Inc.  (NASDAQ:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural
View HTML